Lacerta Bio is a business development consultancy specializing in identifying, assessing, negotiating, and closing licensing and partnership opportunities for the pharmaceutical, biotechnology, and drug delivery industries.

We also work with and support internal business development teams with market research, competitive intelligence, financial modeling, and other support services.

In November, 2014, we announced a merger with Copenhagen-based Ventac Partners. The combination of Lacerta Bio and Ventac Partners will dramatically increase the types of services we can offer our clients, as well as expand our geographic reach.

If you need assistance finding or assessing business development and/or partnership opportunities, contact us at

Current Projects

Seeking Parenteral Products for In-Licensing  
Posted on Jan 21, 2016


Lacerta Bio is seeking parenteral products for in-licensing on behalf of a US-based client.  Key criteria are: Products which can be developed via the 505(b)(2) regulatory process in the US No specific therapeutic area Injectable could be infusion, prefilled syringe, or related presentation Products already approved outside the US are especially welcome Delivery / formulation

  Read More»

Seeking EU Injectables Company or Facilities Acquisitions  
Posted on Mar 02, 2016


  Lacerta Bio is looking to transact a business acquisition opportunity in the European injectables manufacturing sector. We are seeking manufacturing facilities which have the following criteria: Based in Western Europe EU approved manufacturing of parenteral products Could be a stand-alone company which manufactures its own products, or the divestment of a manufacturing facility owned by

  Read More»

China: Opportunities to Access Partnerships and Capital  
Posted on Feb 14, 2015


Would You Like To Expand Your Business Into China? Or Perhaps You Seek An Investor or Development Partner? China is a large and growing opportunity for Western life science companies, as: Life Science in China is Booming – China’s life science industry has been growing at more than 20%+ per year, and is expect to

  Read More»

Our Latest Article

Injectables: Will They Become As Common As Orals? 
Posted on Apr 26, 2016


Our friends at PharmaCircle recently published an interesting and provocative piece entitled Injectables: The New Oral? The PDF is available here.

The article notes that, in 2014, seven of the top ten pharmaceuticals were parenteral products, with products such as Humira, Remicade, and Enbrel achieving $9-12+ billion in sales.

This is a huge change from ten years previously, where only one parenteral product (Epogen) was in the top ten.

The article discusses some of the key reasons why this change has taken place:

  • Complex biologics lack a clear regulatory path for genericization in the US (at least so far). Therefore, there is an inherent exclusivity built into these products, allowing companies to really entrench their brands in their key therapeutic areas…sometime with minimal competition.
  • Parenterals are moving away from vials and bags for infusion and towards patient-friendly prefilled syringes and other technologies for self injection. This reduces the overall cost of therapy while maintaining patient access to these important drugs.
  • Our understanding of cancer and autoimmune diseases has led directly to the development of these biologics. These diseases can now be managed far better today, thanks in part to these parenteral products.

So where do parenterals go from here? We think there are a few areas where parenterals could indeed approach the levels of usage of oral therapies:

Lower Dosing – Highly potent peptides and proteins which can be dosed at ~2 milligrams or less are perfect for any number of self-injection devices, skin-permeating patches, and other delivery devices which can greatly expand their use.

We think low-dose, higher frequency regimens, via novel devices will become more common in the future.

Smaller Large Molecules – Scanning the list of top 10 drugs for 2014, seven are large molecules, and only two (Lantus and Enbrel) are not monoclonal antibodies. Even with Enbrel, we are looking at a molecular weight of roughly 50,000 daltons, while Lantus checks in at a svelte ~6,000 daltons.

As our collective understanding of both disease and drug-target interactions improve, might we see these molecular weights decline? Maybe. Maybe not. But if they do, then self-dosing becomes increasingly possible.

Novel Combinations – Lower doses with small molecules opens up the theoretical possibility of parenteral combination therapies via self-injection. Perhaps small molecules and large peptides/small proteins can be combined in single, self-injection systems for severe inflammation (i.e., later-stage Crohn’s Disease), for maintaining cancer remission, and other medical needs.

Stability issues aside, patients who are using both oral and parenteral therapies could benefit from combining them into a single parenteral. While increasing Rx cost, it could increase compliance and improve overall therapeutic benefit.

So will parenterals ever become as common as orals? Probably not. But the premise of the article is quite sound, in the sense that parenteral products will continue to become more routine, thanks in part to easy-to-use self injection systems and devices.

Latest Posts

On BIO Europe, Regionalism, and Three-Legged Goats 
Posted on Apr 11, 2016

How was Bio Europe in Stockholm last week? The Conference Itself – For us, the conference was terrific. We had nearly 30 high-quality meetings over the three days of partnering, plus more informal meetings and catch-ups at the receptions and dinners. As usual, we did not attend any of the company presentations or round-table discussions,

HBM Pharma/Biotech M&A and New Drug Approvals Reports 
Posted on Mar 15, 2016

  We’re late to the this party, but HBM Partners issued their two annual reports on M&A Activity and New Drug Approvals. Both reports also have Excel files with raw data for analysis. Below are a few highlights which caught our eye: M&A Activity – By numerous measures, 2015 was a record year, especially in terms

The Age of Virtual Pharma: Creative Financing and Exit Models 
Posted on Feb 22, 2016

  At last month’s Biotech Showcase, a panel discussion was held discussing different models for advancing assets without resorting to a license. The link to the discussion is here. It was an interesting discussion because each speaker detailed their own experience in advancing assets without partnering. Examples include risk sharing relationships with CROs and investors. A few

Google Plus   Facebook   Twitter
Powered By : Supra International Inc.